The basal insulins are the most successful insulin class, with other
insulin classes demonstrating high substitution or low and declining
sales. Current basal insulins offer good safety and emerging therapies
are not expected to improve efficacy significantly. However, the launch
of two late-stage pipeline products Degludec and DegludecPlus in 2012–13
will alter market dynamics.
Features and benefits
With strong marketing and sales resources committed by Novo Nordisk, late-stage basal insulin Degludec (insulin degludec) will offer strong competition to class leader Lantus (insulin glargine; Sanofi) and largely cannibalize predecessor Levemir (insulin detemir; Novo Nordisk).
Key patents for blockbuster Lantus will expire from 2014–15. However, the threat of biosimilar insulin is expected to have less impact than typical small molecule generics, as physicians are expected to be reluctant to introduce potential additional variability into patients’ insulin treatment regimens.
Novo Nordisk, Sanofi, and Eli Lilly are also the only companies with promising insulin products in late stage development. Alternative insulin delivery mechanisms under development, such as MannKind’s Afrezza (inhaled insulin), are not expected to make it to market in the near term.
Get Your Copy of Report @ http://www.reportsnreports.com/reports/159563-product-profiles-insulin-antidiabetics-key-developers-compete-for-basal-insulins-market.html
Report Details :
Published: April 2012
No. of Pages: 65
Price: Single User License: US $ 7600 Corporate User License : US $ 19000
Table of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
Published diabetes reports
PRODUCT OVERVIEW
Insulin use in type 1 and type 2 diabetes
Insulin coverage in this report
MARKETED PRODUCT PROFILES
Basal insulin class overview
Lantus (insulin glargine; Sanofi)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Lantus
Clinical and commercial attractiveness
Levemir (insulin detemir; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Levemir
Clinical and commercial attractiveness
Other marketed insulin antidiabetics
Fast-acting insulins
Premixed insulins
PIPELINE PRODUCT PROFILES
Degludec (insulin degludec; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other insulin antidiabetics in development
LY2605541 (Eli Lilly/Boehringer Ingelheim)
Improved basal insulin formulations
Non-injected insulin formulations
Features and benefits
- Understand Datamonitor’s independent appraisal of marketed insulin brands and key pipeline agents indicated for treating type 1 and type 2 diabetes.
- Illustrate how pipeline and marketed insulins compare to one another in terms of clinical and commercial attributes.
- Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
- Understand how marketed insulin brands are positioned in the diabetes treatment algorithm and how they are perceived by prescribers.
- Determine to what extent future insulin therapies satisfy the main clinical unmet needs in the treatment of type 1 and type 2 diabetes.
With strong marketing and sales resources committed by Novo Nordisk, late-stage basal insulin Degludec (insulin degludec) will offer strong competition to class leader Lantus (insulin glargine; Sanofi) and largely cannibalize predecessor Levemir (insulin detemir; Novo Nordisk).
Key patents for blockbuster Lantus will expire from 2014–15. However, the threat of biosimilar insulin is expected to have less impact than typical small molecule generics, as physicians are expected to be reluctant to introduce potential additional variability into patients’ insulin treatment regimens.
Novo Nordisk, Sanofi, and Eli Lilly are also the only companies with promising insulin products in late stage development. Alternative insulin delivery mechanisms under development, such as MannKind’s Afrezza (inhaled insulin), are not expected to make it to market in the near term.
Get Your Copy of Report @ http://www.reportsnreports.com/reports/159563-product-profiles-insulin-antidiabetics-key-developers-compete-for-basal-insulins-market.html
Report Details :
Published: April 2012
No. of Pages: 65
Price: Single User License: US $ 7600 Corporate User License : US $ 19000
Table of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
Published diabetes reports
PRODUCT OVERVIEW
Insulin use in type 1 and type 2 diabetes
Insulin coverage in this report
MARKETED PRODUCT PROFILES
Basal insulin class overview
Lantus (insulin glargine; Sanofi)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Lantus
Clinical and commercial attractiveness
Levemir (insulin detemir; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Levemir
Clinical and commercial attractiveness
Other marketed insulin antidiabetics
Fast-acting insulins
Premixed insulins
PIPELINE PRODUCT PROFILES
Degludec (insulin degludec; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other insulin antidiabetics in development
LY2605541 (Eli Lilly/Boehringer Ingelheim)
Improved basal insulin formulations
Non-injected insulin formulations
